Institute of Human Virology, Nigeria, Maina Court, Central Business District, Abuja, Nigeria.
Demian Foundation of Belgium, Ibadan, Oyo State, Nigeria.
PLoS One. 2018 Aug 22;13(8):e0200810. doi: 10.1371/journal.pone.0200810. eCollection 2018.
Adverse Drug Reactions (ADRs) are a major clinical and public health problem world-wide. The prompt reporting of suspected ADRs to regulatory authorities to activate drug safety surveillance and regulation appears to be the most pragmatic measure for addressing the problem. This paper evaluated a pharmacovigilance (PV) training model that was designed to improve the reporting of ADRs in public health programs treating the Human Immunodeficiency Virus (HIV), Tuberculosis (TB) and Malaria.
A Structured Pharmacovigilance and Training Initiative (SPHAR-TI) model based on the World Health Organization accredited Structured Operational Research and Training Initiative (SOR-IT) model was designed and implemented over a period of 12 months. A prospective cohort design was deployed to evaluate the outcomes of the model. The primary outcomes were knowledge gained and Individual Case Safety Reports (ICSR) (completed adverse drug reactions monitoring forms) submitted, while the secondary outcomes were facility based Pharmacovigilance Committees activated and health facility healthcare workers trained by the participants.
Fifty-five (98%) participants were trained and followed up for 12 months. More than three quarter of the participants have never received training on pharmacovigilance prior to the course. Yet, a significant gain in knowledge was observed after the participants completed a comprehensive training for six days. In only seven months, 3000 ICSRs (with 100% completeness) were submitted, 2,937 facility based healthcare workers trained and 46 Pharmacovigilance Committees activated by the participants. Overall, a 273% increase in ICSRs submission to the National Agency for Food and Drug Administration and Control (NAFDAC) was observed.
Participants gained knowledge, which tended to increase the reporting of ADRs. The SPHAR-TI model could be an option for strengthening the continuous reporting of ADRs in public health programs in resource limited settings.
药物不良反应(ADR)是全球范围内一个主要的临床和公共卫生问题。向监管机构迅速报告疑似 ADR 以启动药物安全监测和监管,似乎是解决这一问题最务实的措施。本文评估了一种旨在提高公共卫生项目中 HIV、结核病和疟疾治疗药物不良反应报告的药物警戒(PV)培训模式。
基于世界卫生组织认可的结构化操作研究和培训倡议(SOR-IT)模型,设计并实施了一个为期 12 个月的结构化药物警戒和培训倡议(SPHAR-TI)模型。采用前瞻性队列设计来评估该模型的结果。主要结果是获得的知识和提交的个体病例安全报告(ICSR)(完成的药物不良反应监测表格),次要结果是激活的以医疗机构为基础的药物警戒委员会和参与者培训的医疗机构卫生保健工作者。
55 名(98%)参与者接受了培训,并随访了 12 个月。超过四分之三的参与者在参加课程之前从未接受过药物警戒培训。然而,在完成为期六天的全面培训后,观察到知识有了显著提高。仅在七个月内,参与者就提交了 3000 份 ICSR(完整性达到 100%),培训了 2937 名医疗机构卫生保健工作者,并激活了 46 个以医疗机构为基础的药物警戒委员会。总体而言,向国家食品和药物管理局和控制机构(NAFDAC)提交的 ICSR 数量增加了 273%。
参与者获得了知识,这有助于增加药物不良反应报告。SPHAR-TI 模型可能是加强资源有限环境下公共卫生项目中药物不良反应持续报告的一种选择。